

Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.: L74899DL1993PLC056594

**Ref: STEX/INTIMATION/2025-26**

**Date: May 22, 2025**

**BSE Limited**

Department of Corporate Services-Listing  
PJ Towers, Dalal Street  
Mumbai- 400001

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra Kurla Complex  
Bandra (E) Mumbai- 400051

**Scrip Code- 531146**

**Symbol- MEDICAMEQ**

**Subject: Intimation under SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 - Board Meeting  
– May 30, 2025**

Pursuant to Regulation 29 read with Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited ('the Company') is scheduled to be held on Friday, May 30, 2025 at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 to inter-alia, consider and approve the following business(s):

1. The Audited Financial Results of the Company (Standalone and Consolidated) for the quarter / year ended on March 31, 2025
2. To consider the recommend Final Dividend on Equity Shares of the Company for the financial year 2024-25, if any.
3. To consider and appoint M/s SPB & Co, Cost Accountants, as the Cost Auditor of the company for the financial year 2025-26.
4. To consider and appoint M/s Cheena & Associates, as the Internal Auditor of the company for the financial year 2025-26.
5. To consider and appoint M/s AMJ & Associates, Company Secretaries as Secretarial Auditor of the Company for a period of 5 years subject to the approval of shareholders in the ensuing General Meeting of the Company.
6. Any other business with the permission of the chair.

Further, in accordance with the SEBI (Prevention of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Company's securities was closed from April 1, 2025 and will open 48 hours after the said Financial Results are declared to Stock Exchanges.

This is for your information and record.

Yours faithfully

**for Medicamen Biotech Limited**

**Parul Choudhary**  
**Company Secretary & Compliance Officer**  
**ACS44157**